

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use CLOZARIL safely and effectively. See full prescribing information for CLOZARIL.

CLOZARIL® (clozapine) tablets, for oral use  
Initial U.S. Approval: 1989

**WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPES; SEIZURE; MYOCARDITIS, PERICARDITIS, AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS**

*See full prescribing information for complete boxed warning.*

- **Severe Neutropenia:** CLOZARIL has caused severe neutropenia, which is associated with an increased risk of serious and fatal infections. Prior to initiating CLOZARIL treatment, obtain baseline ANC(s). CLOZARIL initiation is not recommended in patients with a baseline ANC less than 1500/ $\mu$ L (less than 1000/ $\mu$ L for those with Benign Ethnic Neutropenia (also known as Duffy-null associated neutrophil count)). See recommendations for dosage modifications based on ANC levels during CLOZARIL treatment (2.3, 2.4, 5.1).
- **Orthostatic Hypotension, Bradycardia, and Syncope:** Risk is dose-related. Starting dose is 12.5 mg. Titrate gradually and use divided dosages. (2.2, 2.6, 5.2)
- **Seizure:** Risk is dose-related. Titrate gradually and use divided doses. Use with caution in patients with history of seizure or risk factors for seizure. (2.2, 5.4)
- **Myocarditis, Pericarditis, Cardiomyopathy and Mitral Valve Incompetence:** Can be fatal. Discontinue and obtain cardiac evaluation if findings suggest these cardiac reactions. (5.5)
- **Increased Mortality in Elderly Patients with Dementia-Related Psychosis:** CLOZARIL is not approved for this condition. (5.6)

## RECENT MAJOR CHANGES

Boxed Warning	6/2025
Dosage and Administration (2)	6/2025
Warnings and Precautions (5.1)	6/2025
Warnings and Precautions (5.5)	1/2025

## INDICATIONS AND USAGE

CLOZARIL is an atypical antipsychotic indicated for:

- Treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, CLOZARIL should be used only in patients who have failed to respond adequately to standard antipsychotic treatment. (1.1)
- Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior. (1.2)

## DOSAGE AND ADMINISTRATION

- Recommended starting oral dosage is 12.5 mg once daily or twice daily. (2.2)
- If well-tolerated, increase the total daily dosage in increments of 25 mg to 50 mg per day to achieve a target dosage of 150 mg to 225 mg twice per day by the end of two weeks (2.2).
- Subsequently may increase the dosage in increments up to 100 mg once or twice weekly. (2.2)
- Maximum daily dosage is 450 mg twice daily (2.2)
- Administer with or without food (2.2).
- See the dosage modifications based on ANC results and recommended frequency of ANC testing in the full prescribing information (2.3, 2.4).
- See recommendations for discontinuing CLOZARIL treatment (2.5), restarting CLOZARIL after interrupting dosing (2.6), dosage modifications for drug interactions (2.7), dosage recommendations in patients with renal or hepatic impairment and CYP2D6 poor metabolizers (2.8) in the full prescribing information.

## DOSAGE FORMS AND STRENGTHS

25 mg and 100 mg tablets with a facilitated score on one side (3)

## CONTRAINDICATIONS

Known hypersensitivity to clozapine or any other component of CLOZARIL. (4)

## WARNINGS AND PRECAUTIONS

- **Severe neutropenia:** See Boxed Warning (5.1)
- **Gastrointestinal Hypomotility with Severe Complications:** Severe gastrointestinal adverse reactions have occurred with the use of CLOZARIL. If constipation is identified, close monitoring and prompt treatment is advised. (5.7)
- **Eosinophilia:** Assess for organ involvement (e.g., myocarditis, pancreatitis, hepatitis, colitis, nephritis). Discontinue if these occur. (5.8)
- **QT Interval Prolongation:** Can be fatal. Consider additional risk factors for prolonged QT interval (disorders and drugs). (5.9)
- **Metabolic Changes:** Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.

These metabolic changes include:

- **Hyperglycemia and Diabetes Mellitus:** Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. (5.10)
- **Dyslipidemia:** Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics. (5.10)
- **Weight Gain:** Significant weight gain has occurred. Monitor weight gain. (5.10)
- **Neuroleptic Malignant Syndrome (NMS):** Immediately discontinue and monitor closely. Assess for co-morbid conditions. (5.11)
- **Hepatotoxicity:** Can be fatal. Monitor for hepatotoxicity. Discontinue treatment if hepatitis or transaminase elevations combined with other symptoms occur (5.12).
- **Fever:** Evaluate for infection and for neutropenia, NMS. (5.13)
- **Pulmonary Embolism (PE):** Consider PE if respiratory distress, chest pain, or deep-vein thrombosis occur. (5.14)
- **Anticholinergic Toxicity:** When possible, avoid use with other anticholinergic drugs and use with caution in patients with a current diagnosis or prior history of constipation, urinary retention, clinically significant prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse reactions. (5.15, 7.1)
- **Interference with Cognitive and Motor Performance:** Advise caution when operating machinery, including automobiles. (5.16)

## ADVERSE REACTIONS

Most common adverse reactions ( $\geq 5\%$ ) were: CNS reactions (sedation, dizziness/vertigo, headache, and tremor); cardiovascular reactions (tachycardia, hypotension, and syncope); autonomic nervous system reactions (hypersalivation, sweating, dry mouth, and visual disturbances); gastrointestinal reactions (constipation and nausea); and fever. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact HLS Therapeutics (USA), Inc. at (844) 457-8721 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

## DRUG INTERACTIONS

- **Concomitant use of Strong CYP1A2 Inhibitors:** Reduce CLOZARIL dose to one-third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin). (2.7, 7.1)
- **Concomitant use of Strong CYP3A4 Inducers** is not recommended. (2.7, 7.1)
- **Discontinuation of CYP1A2 or CYP3A4 Inducers:** Consider reducing CLOZARIL dose when CYP1A2 inducers (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued. (2.7, 7.1)
- **Anticholinergic drugs:** Concomitant use may increase the risk for anticholinergic toxicity. (5.7, 5.15, 7.1)

## USE IN SPECIFIC POPULATIONS

- **Pregnancy:** May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure (8.1).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised 6/2025

---

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPES; SEIZURE; MYOCARDITIS, PERICARDITIS, AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS**

**1 INDICATIONS AND USAGE**

- 1.1 Treatment-Resistant Schizophrenia
- 1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

**2 DOSAGE AND ADMINISTRATION**

- 2.1 Absolute Neutrophil Count Testing Prior to CLOZARIL Initiation
- 2.2 Recommended Dosage and Administration
- 2.3 Dosage Modifications Based on ANC Results
- 2.4 Dosage Modifications Based on ANC Results for Patients with Benign Ethnic Neutropenia
- 2.5 Discontinuation of CLOZARIL Treatment
- 2.6 Restarting CLOZARIL Treatment After Interrupting CLOZARIL
- 2.7 Dosage Modifications for Drug Interactions
- 2.8 Dosage Recommendations in Patients with Renal or Hepatic Impairment, or CYP2D6 Poor Metabolizers

**3 DOSAGE FORMS AND STRENGTHS****4 CONTRAINDICATIONS****5 WARNINGS AND PRECAUTIONS**

- 5.1 Severe Neutropenia
- 5.2 Orthostatic Hypotension, Bradycardia, and Syncope
- 5.3 Falls
- 5.4 Seizures
- 5.5 Myocarditis, Pericarditis, Cardiomyopathy and Mitral Valve Incompetence
- 5.6 Increased Mortality in Elderly Patients with Dementia-Related Psychosis
- 5.7 Gastrointestinal Hypomotility with Severe Complications
- 5.8 Eosinophilia
- 5.9 QT Interval Prolongation
- 5.10 Metabolic Changes
- 5.11 Neuroleptic Malignant Syndrome
- 5.12 Hepatotoxicity
- 5.13 Fever

- 5.14 Pulmonary Embolism
- 5.15 Anticholinergic Toxicity
- 5.16 Interference with Cognitive and Motor Performance
- 5.17 Tardive Dyskinesia
- 5.18 Cerebrovascular Adverse Reactions
- 5.19 Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation of CLOZARIL

**6 ADVERSE REACTIONS**

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

**7 DRUG INTERACTIONS**

- 7.1 Potential for Other Drugs to Affect CLOZARIL
- 7.2 Potential for CLOZARIL to Affect Other Drugs

**8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Patients with Renal or Hepatic Impairment
- 8.7 CYP2D6 Poor Metabolizers

**10 OVERDOSAGE**

- 10.1 Overdosage Experience
- 10.2 Management of Overdosage

**11 DESCRIPTION****12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

**13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**14 CLINICAL STUDIES**

- 14.1 Treatment-Resistant Schizophrenia
- 14.2 Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

**16 HOW SUPPLIED/STORAGE AND HANDLING**

- 16.1 How Supplied
- 16.2 Storage and Handling

**17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed

---

## FULL PRESCRIBING INFORMATION

### **WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; MYOCARDITIS, PERICARDITIS, AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS**

#### **Severe Neutropenia**

CLOZARIL has caused severe neutropenia which is associated with an increased risk of serious and potentially fatal infections. Prior to initiating CLOZARIL treatment, obtain baseline ANC(s). CLOZARIL initiation is not recommended in patients with a baseline ANC less than 1500/ $\mu$ L (less than 1000/ $\mu$ L for those with Benign Ethnic Neutropenia (also known as Duffy-null associated neutrophil count)). See recommendations for dosage modifications based on ANC levels during CLOZARIL treatment [see *Dosage and Administration (2.3, 2.4)*]. Consider a hematology consultation before initiating CLOZARIL or during CLOZARIL treatment [see *Warnings and Precautions (5.1)*].

#### **Orthostatic Hypotension, Bradycardia, Syncope**

Orthostatic hypotension, bradycardia, syncope, and cardiac arrest have occurred with CLOZARIL treatment. The risk is highest during the initial titration period, particularly with rapid dose escalation. These reactions can occur with the first dose, with doses as low as 12.5 mg per day, or when restarting patients who have had even a brief interruption in treatment with CLOZARIL. Initiate treatment at 12.5 mg once or twice daily; titrate slowly; and use divided dosages to minimize risk. Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see *Dosage and Administration (2.2, 2.6), Warnings and Precautions (5.2)*].

#### **Seizures**

Seizures have occurred with CLOZARIL treatment. The risk is dose-related. Initiate treatment at 12.5 mg, titrate gradually, and use divided dosing. Use caution when administering CLOZARIL to patients with a history of seizures or other predisposing risk factors for seizure (CNS pathology, medications that lower the seizure threshold, alcohol abuse). Caution patients about engaging in any activity where sudden loss of consciousness could cause serious risk to themselves or others [see *Dosage and Administration (2.2), Warnings and Precautions (5.4)*].

#### **Myocarditis, Pericarditis, Cardiomyopathy and Mitral Valve Incompetence**

Fatal myocarditis and cardiomyopathy have occurred with CLOZARIL treatment. Discontinue CLOZARIL and obtain a cardiac evaluation upon suspicion of these reactions. Generally, patients with CLOZARIL-related myocarditis or cardiomyopathy should not be rechallenged with CLOZARIL. Consider the possibility of myocarditis, pericarditis, or cardiomyopathy if chest pain, tachycardia, palpitations, dyspnea, fever, flu-like symptoms, hypotension, or ECG changes occur [see *Warnings and Precautions (5.5)*].

#### **Increased Mortality in Elderly Patients with Dementia-Related Psychosis**

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CLOZARIL is not approved for use in patients with dementia-related psychosis [see *Warnings and Precautions (5.6)*].

## 1 INDICATIONS AND USAGE

### 1.1 Treatment-Resistant Schizophrenia

CLOZARIL is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, CLOZARIL should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see *Warnings and Precautions (5.1, 5.4)*].

The effectiveness of CLOZARIL in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing CLOZARIL and chlorpromazine in patients who had failed other antipsychotics [see *Clinical Studies (14.1)*].

## 1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

CLOZARIL is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death.

The effectiveness of CLOZARIL in reducing the risk of recurrent suicidal behavior was demonstrated over a two-year treatment period in the InterSePT™ trial [see *Clinical Studies (14.2)*].

## 2 DOSAGE AND ADMINISTRATION

### 2.1 Absolute Neutrophil Count Testing Prior to CLOZARIL Initiation

Prior to initiating CLOZARIL treatment, obtain a baseline absolute neutrophil count (ANC). CLOZARIL initiation is not recommended in patients with an ANC less than 1500/ $\mu$ L [see *Warnings and Precautions (5.1)*].

For patients with documented Benign Ethnic Neutropenia (BEN) (also known as Duffy-null associated neutrophil count), obtain at least two baseline ANC levels. CLOZARIL initiation is not recommended in patients with BEN with an ANC less than 1000/ $\mu$ L [see *Warnings and Precautions (5.1)*].

For dosage modifications based on ANC results, see *Dosage and Administration (2.3, 2.4)*.

### 2.2 Recommended Dosage and Administration

To reduce the risk of orthostatic hypotension, bradycardia, and syncope, the recommended starting dosage is much lower than the target dosage [see *Warnings and Precautions (5.2)*].

CLOZARIL can be taken with or without food [see *Clinical Pharmacology (12.3)*]. The recommended starting oral dosage of CLOZARIL is 12.5 mg once or twice daily. If well-tolerated, increase the total daily dose in increments of 25 mg to 50 mg per day to achieve a target dosage of 150 mg to 225 mg twice per day by the end of two weeks. Subsequently, may increase the dosage in increments of up to 100 mg once weekly or twice weekly. The maximum recommended CLOZARIL oral dosage is 450 mg twice daily.

### 2.3 Dosage Modifications Based on ANC Results

Table 1 provides recommended CLOZARIL dosage modifications based on ANC results [see *Warnings and Precautions (5.1)*]. For dosage modifications based on ANC results for patients with Benign Ethnic Neutropenia (BEN) (also known as Duffy-null associated neutrophil count), see Table 2 [see *Dosage and Administration (2.4)*].

**Table 1. CLOZARIL Dosage Modifications Based on ANC Results and Frequency of ANC Testing**

Recommended Dosage Modification	Recommended Frequency of ANC Testing During CLOZARIL Treatment
<b>ANC Within Normal Range (<math>\geq 1500/\mu</math>L)</b>	
No dosage modification; continue treatment	<ul style="list-style-type: none"><li>Day 1 to Month 6: Weekly</li><li>Month 7 to Month 12: Every 2 weeks</li><li>Month 13 and thereafter: Every month</li></ul> If CLOZARIL treatment is reinitiated after a dosage interruption (e.g., patient had neutropenia which required dosage interruption and now has a normal ANC level) for: <ul style="list-style-type: none"><li>&lt; 30 days, continue the previous ANC testing frequency</li><li><math>\geq 30</math> days, obtain ANC tests according to the frequency for patients who initiate treatment</li></ul>
<b>Mild Neutropenia (ANC between 1000 to 1499/<math>\mu</math>L)<sup>1</sup></b>	
No dosage modification; continue treatment	<ul style="list-style-type: none"><li>Three times weekly</li><li>Once ANC <math>\geq 1500/\mu</math>L, recommend returning to the patient's last <b>Normal Range</b> ANC testing frequency</li></ul>
<b>Moderate Neutropenia (ANC between 500 to 999/<math>\mu</math>L)<sup>1</sup></b>	
<ul style="list-style-type: none"><li>Interrupt treatment and recommend hematology consultation</li></ul>	<ul style="list-style-type: none"><li>Daily</li><li>Once ANC <math>\geq 1000/\mu</math>L, three times weekly</li></ul>

<ul style="list-style-type: none"> <li>Resume treatment once ANC <math>\geq 1000/\mu\text{L}</math></li> </ul>	<ul style="list-style-type: none"> <li>Once ANC <math>\geq 1500/\mu\text{L}</math>, test weekly for 4 weeks. If ANC <math>\geq 1500/\mu\text{L}</math> after monitoring weekly for 4 weeks, return to the patient's last <b>Normal Range</b> ANC testing frequency</li> </ul>
<b>Severe Neutropenia (ANC less than <math>500/\mu\text{L}</math>)<sup>1</sup></b>	
Discontinue treatment and recommend hematology consultation	<ul style="list-style-type: none"> <li>Daily</li> <li>Once ANC <math>\geq 1000/\mu\text{L}</math>, three times weekly</li> <li>Once ANC <math>\geq 1500/\mu\text{L}</math>, if the benefits outweigh the risks of restarting treatment, resume treatment and obtain ANC tests according to the frequency for patients who initiate treatment</li> </ul>

<sup>1</sup> Confirm all initial reports of ANC less than  $1500/\mu\text{L}$  with a repeat ANC measurement within 24 hours.

## 2.4 Dosage Modifications Based on ANC Results for Patients with Benign Ethnic Neutropenia

Table 2 provides recommended CLOZARIL dosage modifications based on ANC results for patients with Benign Ethnic Neutropenia (BEN) (also known as Duffy-null associated neutrophil count) [see *Warnings and Precautions (5.1)*]. For dosage modifications based on ANC results for patients without BEN, see Table 1 [see *Dosage and Administration (2.3)*].

**Table 2. CLOZARIL Dosage Modifications Based on ANC Results and Frequency of ANC Testing in Patients with Benign Ethnic Neutropenia<sup>1</sup>**

Recommended Dosage Modification	Recommended Frequency of ANC Testing During CLOZARIL Treatment in Patients with BEN
<b>ANC Within the Normal Range for Patients with BEN (<math>\geq 1000/\mu\text{L}</math>)</b>	
No dosage modification; continue treatment	<ul style="list-style-type: none"> <li>Day 1 to Month 6: Weekly</li> <li>Month 7 to Month 12: Every 2 weeks</li> <li>Month 13 and thereafter: Monthly</li> </ul>
	If CLOZARIL treatment is reinitiated after a dosage interruption (e.g., patient had neutropenia which required dosage interruption and now their ANC ( $\geq 1000/\mu\text{L}$ and $\geq$ the patient's ANC baseline prior to treatment) for: <ul style="list-style-type: none"> <li>&lt; 30 days, continue previous ANC testing frequency</li> <li><math>\geq 30</math> days, obtain ANC tests according to the frequency for patients with BEN who initiate treatment</li> </ul>
<b>Neutropenia in Patients with BEN (ANC level between <math>500</math> to <math>999/\mu\text{L}</math>)<sup>2</sup></b>	
<ul style="list-style-type: none"> <li>Recommend hematology consultation</li> <li>No dosage modification; continue treatment</li> </ul>	<ul style="list-style-type: none"> <li>Three times weekly</li> <li>Once ANC <math>\geq 1000/\mu\text{L}</math> and <math>\geq</math> the patient's ANC baseline, obtain ANC tests weekly for 4 weeks</li> <li>If ANC <math>\geq 1000/\mu\text{L}</math> and <math>\geq</math> the patient's baseline after monitoring for 4 weeks, return to the patient's last <b>Normal ANC Range</b> testing frequency for patients with BEN</li> </ul>
<b>Severe Neutropenia in Patients with BEN (ANC level less than <math>500/\mu\text{L}</math>)<sup>2</sup></b>	
Discontinue treatment and recommend hematology consultation	<ul style="list-style-type: none"> <li>Daily</li> <li>Once ANC <math>\geq 500/\mu\text{L}</math>, obtain ANC three times weekly</li> <li>Once ANC <math>\geq 1000/\mu\text{L}</math> and <math>\geq</math> the patient's baseline, if the benefits outweigh the risks of restarting treatment, resume treatment and obtain ANC tests according to the frequency for patients with BEN who initiate treatment</li> </ul>

<sup>1</sup> Benign Ethnic Neutropenia (BEN) is also known as Duffy-null associated neutrophil count.

<sup>2</sup> Confirm all initial reports of ANC less than  $1500/\mu\text{L}$  with a repeat ANC measurement within 24 hours

## 2.5 Discontinuation of CLOZARIL Treatment

If discontinuing CLOZARIL in patients with:

- Moderate or severe neutropenia, see Table 1 [see *Dosage and Administration (2.3)*].
- Normal or mild neutropenia, reduce the dosage gradually over a period of 1 to 2 weeks, and continue monitoring ANC levels until their ANC is  $\geq 1500/\mu\text{L}$ .

If discontinuing CLOZARIL in patients with Benign Ethnic Neutropenia (BEN) (also known as Duffy-null associated neutrophil count) with:

- Neutropenia, see [Table 2](#) [*see Dosage and Administration (2.4)*].
- ANC within their normal range of ANC reduce the dosage gradually over a period of 1 to 2 weeks.

When discontinuing CLOZARIL, monitor patients for the symptoms related to psychotic recurrence and cholinergic rebound (e.g., profuse sweating, headache, nausea, vomiting, diarrhea).

## 2.6 Restarting CLOZARIL Treatment After Interrupting CLOZARIL

When restarting CLOZARIL in patients who have interrupted CLOZARIL treatment, use a lower dosage to minimize the risk of hypotension, bradycardia, and syncope [*see Warnings and Precautions (5.2)*].

- If one day's dosage is missed, resume CLOZARIL treatment at 40% to 50% of the previous dosage.
- If two days of dosing is missed, resume CLOZARIL treatment at approximately 25% of the previous dosage.
- For longer interruptions, restart CLOZARIL treatment with a dosage of 12.5 mg once or twice daily. If this dosage is well-tolerated, may increase the dosage to the previous dosage more quickly than recommended than for initial CLOZARIL treatment.

## 2.7 Dosage Modifications for Drug Interactions

See [Table 3](#) for recommended dosage modifications to reduce the risk of CLOZARIL-associated adverse reactions or reduce the risk of lower effectiveness [*see Drug Interactions (7)*].

**Table 3. CLOZARIL Dosage Modifications for Drug Interactions**

Strong CYP1A2 Inhibitors	Administer one third of the CLOZARIL dosage.
Moderate or Weak CYP1A2 Inhibitors	Consider reducing the CLOZARIL dosage if necessary.
CYP2D6 or CYP3A4 Inhibitors	
Strong CYP3A4 Inducers	Concomitant use is not recommended. However, if concomitant use is necessary, it may be necessary to increase the CLOZARIL dosage. Monitor for decreased effectiveness.
Moderate or weak CYP1A2 or CYP3A4 Inducers	Consider increasing the CLOZARIL dosage if necessary.

## 2.8 Dosage Recommendations in Patients with Renal or Hepatic Impairment, or CYP2D6 Poor Metabolizers

It may be necessary to reduce the CLOZARIL dosage in patients with significant renal impairment or hepatic impairment, or in CYP2D6 poor metabolizers [*see Use in Specific Populations (8.6, 8.7)*].

## 3 DOSAGE FORMS AND STRENGTHS

Tablets: 25 mg and 100 mg round, pale-yellow, with a facilitated score on one side.

## 4 CONTRAINDICATIONS

CLOZARIL is contraindicated in patients with a history of hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson syndrome) or any other component of CLOZARIL [*see Adverse Reactions (6.2)*].

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Severe Neutropenia

CLOZARIL has caused severe neutropenia (absolute neutrophil count (ANC) less than 500/ $\mu$ L) [see *Adverse Reactions (6.1, 6.2)*] and is associated with an increased risk of serious and potentially fatal infections. Severe neutropenia occurred in a small percentage of CLOZARIL-treated patients. The risk of severe neutropenia appears greatest during the first 18 weeks of CLOZARIL treatment. The mechanism by which CLOZARIL causes neutropenia is unknown. Neutropenia is not dose dependent.

Consider a hematology consultation before initiating CLOZARIL treatment or during treatment.

#### ANC Monitoring and Dosage Modifications

Prior to initiating CLOZARIL treatment, obtain a baseline ANC. CLOZARIL initiation is not recommended in patients with a baseline ANC less than 1500/ $\mu$ L. Throughout CLOZARIL treatment, regularly monitor ANC. Table 1 provides recommendations for dosage modifications (dosage interruption and treatment discontinuation), based on ANC levels, during CLOZARIL treatment and frequency of ANC monitoring [see *Dosage and Administration (2.3)*].

#### ANC Monitoring and Dosage Modification in Patients with Benign Ethnic Neutropenia

Patients with Benign Ethnic Neutropenia (BEN) (also known as Duffy-null associated neutrophil count) generally have lower baseline neutrophil counts but they are not at higher risk for developing infections, and they are not at increased risk for developing CLOZARIL-induced neutropenia.

For patients with documented BEN, obtain at least two baseline ANC levels prior to CLOZARIL initiation. CLOZARIL initiation is not recommended in patients with BEN with an ANC less than 1000/ $\mu$ L. There are different ANC dosage modification recommendations in CLOZARIL-treated patients with BEN due to their lower baseline ANC levels. Table 2 provides recommendations on dosage modifications (dosage interruption and treatment discontinuation), based on ANC monitoring, during CLOZARIL treatment in patients with BEN and recommended frequency of ANC testing [see *Dosage and Administration (2.4)*].

#### Management of CLOZARIL-Treated Patients Who Develop a Fever

For patients who develop a fever during CLOZARIL treatment:

- Interrupt CLOZARIL in those who develop a temperature of 101.3 °F (38.5 °C) or greater and obtain an ANC level.
- If the ANC is less than 1000/ $\mu$ L in patients without BEN, initiate appropriate workup and treatment for infection. Refer to Table 1 or Table 2 for dosage modifications based on ANC monitoring [see *Dosage and Administration (2.3,2.4)*].

In patients with fever and a normal neutrophil count, see *Warnings and Precautions (5.11)* for neuroleptic malignant syndrome and *Warnings and Precautions (5.13)* for fever.

#### Restarting CLOZARIL in Patients Who Recovered from Severe Neutropenia

Generally, do not rechallenge patients with CLOZARIL in those who experienced severe neutropenia. However, for some patients who had resolution of their CLOZARIL-related severe neutropenia after stopping CLOZARIL, the risk of schizophrenia exacerbation from not restarting CLOZARIL treatment may be greater than the risk of neutropenia reoccurrence from restarting CLOZARIL (e.g., patients who have no treatment options other than CLOZARIL).

#### Concomitant Use of CLOZARIL with Other Drugs Known to Cause Neutropenia

If CLOZARIL is used concomitantly with another drug known to cause neutropenia, consider more frequently ANC monitoring than the recommendations provided in Table 1 and Table 2.

## 5.2 Orthostatic Hypotension, Bradycardia, and Syncope

Hypotension, bradycardia, syncope, and cardiac arrest have occurred with clozapine treatment. The risk is highest during the initial titration period, particularly with rapid dose-escalation. These reactions can occur with the first dose, at doses as low as 12.5 mg. These reactions can be fatal. The syndrome is consistent with neurally mediated reflex bradycardia (NMRB).

Treatment must begin at a maximum dose of 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of 2 weeks. Subsequently, the dose can be increased weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. Use cautious titration and a divided dosage schedule to minimize the risk of serious cardiovascular reactions [see *Dosage and Administration (2.2)*]. Consider reducing the dose if hypotension occurs. When restarting CLOZARIL in patients who have had even a brief interruption in treatment with CLOZARIL, the dosage must be reduced. This is necessary to minimize the risk of hypotension, bradycardia, and syncope [see *Dosage and Administration (2.6)*].

Use CLOZARIL cautiously in patients with cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (e.g., concomitant use of antihypertensives, dehydration and hypovolemia).

## 5.3 Falls

CLOZARIL may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.

## 5.4 Seizures

Seizure has been estimated to occur in association with clozapine use at a cumulative incidence at one year of approximately 5%, based on the occurrence of one or more seizures in 61 of 1743 patients exposed to clozapine during its clinical testing prior to domestic marketing (i.e., a crude rate of 3.5%). The risk of seizure is dose-related. Initiate treatment with a low dose (12.5 mg), titrate slowly, and use divided dosing.

Use caution when administering CLOZARIL to patients with a history of seizures or other predisposing risk factors for seizure (e.g., head trauma or other CNS pathology, use of medications that lower the seizure threshold, or alcohol abuse). Because of the substantial risk of seizure associated with CLOZARIL use, caution patients about engaging in any activity where sudden loss of consciousness could cause serious risk to themselves or others (e.g., driving an automobile, operating complex machinery, swimming, climbing).

## 5.5 Myocarditis, Pericarditis, Cardiomyopathy and Mitral Valve Incompetence

Myocarditis, pericarditis, and cardiomyopathy have occurred with the use of CLOZARIL. These reactions can be fatal. Discontinue CLOZARIL and obtain a cardiac evaluation upon suspicion of myocarditis, pericarditis, or cardiomyopathy. Generally, patients with a history of clozapine-associated myocarditis or cardiomyopathy should not be rechallenged with CLOZARIL. However, if the benefit of CLOZARIL treatment is judged to outweigh the potential risks of recurrence, the clinician may consider challenge with CLOZARIL in consultation with a cardiologist.

Myocarditis and pericarditis most frequently present within the first 2 months of clozapine treatment. Symptoms of cardiomyopathy generally occur later than clozapine-associated myocarditis or pericarditis and usually after 8 weeks of treatment. However, myocarditis, pericarditis, and cardiomyopathy can occur at any period during treatment with CLOZARIL. In patients who are diagnosed with cardiomyopathy while taking CLOZARIL mitral valve incompetence has been reported.

## 5.6 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.

Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality in this population. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. CLOZARIL is not approved for the treatment of patients with dementia-related psychosis [see *Boxed Warning*].

### **5.7 Gastrointestinal Hypomotility with Severe Complications**

Severe gastrointestinal adverse reactions have occurred with the use of CLOZARIL, primarily due to its potent anticholinergic effects and resulting gastrointestinal hypomotility. In post marketing experience, reported effects range from constipation to paralytic ileus. Increased frequency of constipation and delayed diagnosis and treatment increased the risk of severe complications of gastrointestinal hypomotility, which can result in fecal impaction, megacolon, and intestinal obstruction, ischemia, infarction, perforation, ulceration, or necrosis [see *Adverse Reaction (6.2)*]. These reactions have resulted in hospitalization, surgery, and death. The risk of severe adverse reactions is further increased with anticholinergic medications (and other medications that decrease gastrointestinal peristalsis); therefore, concomitant use should be avoided when possible [see *Warnings and Precautions (5.15)*, *Drug Interactions (7.1)*].

Prior to initiating CLOZARIL, screen for constipation and treat as necessary. Subjective symptoms of constipation may not accurately reflect the degree of gastrointestinal hypomotility in CLOZARIL treated patients. Therefore, reassess bowel function frequently with careful attention to any changes in the frequency or character of bowel movements, as well as signs and symptoms of complications of hypomotility (e.g., nausea, vomiting, abdominal distension, abdominal pain). If constipation or gastrointestinal hypomotility are identified, monitor closely and treat promptly with appropriate laxatives, as necessary, to prevent severe complications. Consider prophyllactic laxatives in high risk patients.

### **5.8 Eosinophilia**

Eosinophilia, defined as a blood eosinophil count of greater than 700/ $\mu$ L, has occurred with CLOZARIL treatment. In clinical trials, approximately 1% of patients developed eosinophilia. Clozapine-related eosinophilia usually occurs during the first month of treatment. In some patients, it has been associated with myocarditis, pancreatitis, hepatitis, colitis, and nephritis. Such organ involvement could be consistent with a drug reaction with eosinophilia and systemic symptoms syndrome (DRESS), also known as drug induced hypersensitivity syndrome (DIHS). If eosinophilia develops during CLOZARIL treatment, evaluate promptly for signs and symptoms of systemic reactions, such as rash or other allergic symptoms, myocarditis, or other organ-specific disease associated with eosinophilia. If CLOZARIL-related systemic disease is suspected, discontinue CLOZARIL immediately.

If a cause of eosinophilia unrelated to CLOZARIL is identified (e.g., asthma, allergies, collagen vascular disease, parasitic infections, and specific neoplasms), treat the underlying cause and continue CLOZARIL.

Clozapine-related eosinophilia has also occurred in the absence of organ involvement and can resolve without intervention. There are reports of successful rechallenge after discontinuation of clozapine, without recurrence of eosinophilia. In the absence of organ involvement, continue CLOZARIL under careful monitoring. If the total eosinophil count continues to increase over several weeks in the absence of systemic disease, the decision to interrupt CLOZARIL therapy and rechallenge after the eosinophil count decreases should be based on the overall clinical assessment, in consultation with an internist or hematologist.

### **5.9 QT Interval Prolongation**

QT prolongation, Torsade de Pointes and other life-threatening ventricular arrhythmias, cardiac arrest, and sudden death have occurred with CLOZARIL treatment. When prescribing CLOZARIL, consider the presence of additional risk factors for QT prolongation and serious cardiovascular reactions. Conditions that increase these risks include the following: history of QT prolongation, long QT syndrome, family history of long QT syndrome or sudden cardiac death, significant cardiac arrhythmia, recent myocardial infarction, uncompensated heart failure, treatment with other medications that cause QT prolongation, treatment with medications that inhibit the metabolism of clozapine, and electrolyte abnormalities.

Prior to initiating treatment with CLOZARIL, perform a careful physical examination, medical history, and concomitant medication history. Consider obtaining a baseline ECG and serum chemistry panel. Correct electrolyte abnormalities. Discontinue CLOZARIL if the QTc interval exceeds 500 msec. If patients experience symptoms consistent with Torsades de Pointes, or other arrhythmias (e.g., syncope, presyncope, dizziness, or palpitations), obtain a cardiac evaluation and discontinue CLOZARIL.

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of CLOZARIL. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone,

chlorpromazine, thioridazine, mesoridazine, droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). Clozapine is primarily metabolized by CYP isoenzymes 1A2, 2D6, and 3A4. Concomitant treatment with inhibitors of these enzymes can increase the concentration of CLOZARIL [see *Drug Interactions (7.1) and Clinical Pharmacology (12.3)*].

Hypokalemia and hypomagnesemia increase the risk of QT prolongation. Hypokalemia can result from diuretic therapy, diarrhea, and other causes. Use caution when treating patients at risk for significant electrolyte disturbance, particularly hypokalemia. Obtain baseline measurements of serum potassium and magnesium levels, and periodically monitor electrolytes. Correct electrolyte abnormalities before initiating treatment with CLOZARIL.

### **5.10 Metabolic Changes**

Atypical antipsychotic drugs, including CLOZARIL have been associated with metabolic changes that can increase cardiovascular and cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While atypical antipsychotic drugs may produce some metabolic changes, each drug in the class has its own specific risk profile.

#### *Hyperglycemia and Diabetes Mellitus*

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including CLOZARIL. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics are not available.

Patients with an established diagnosis of diabetes mellitus who are started on CLOZARIL should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug.

In a pooled data analysis of 8 studies in adult subjects with schizophrenia, the mean changes in fasting glucose concentration in the CLOZARIL and chlorpromazine groups were +11 mg/dL and +4 mg/dL respectively. A higher proportion of the CLOZARIL group demonstrated categorical increases from baseline in fasting glucose concentrations, compared to the chlorpromazine group (Table 4). The CLOZARIL doses were 100–900 mg per day (mean modal dose: 512 mg per day). The maximum chlorpromazine dose was 1800 mg per day (mean modal dose: 1029 mg per day). The median duration of exposure was 42 days for CLOZARIL and chlorpromazine.

**Table 4. Categorical Changes in Fasting Glucose Level in Studies in Adult Subjects with Schizophrenia**

Laboratory Parameter	Category Change (at least once) from baseline	Treatment Arm	N	n (%)
Fasting Glucose	Normal (<100 mg/dL) to High (≥126 mg/dL)	CLOZARIL	198	53 (27)
		Chlorpromazine	135	14 (10)
	Borderline (100 to 125 mg/dL) to High (≥126 mg/dL)	CLOZARIL	57	24 (42)
		Chlorpromazine	43	12 (28)

*Dyslipidemia*

Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics, including CLOZARIL. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using CLOZARIL, is recommended.

In a pooled data analysis of 10 studies in adult subjects with schizophrenia, CLOZARIL treatment was associated with increases in serum total cholesterol. No data were collected on LDL and HDL cholesterol. The mean increase in total cholesterol was 13 mg/dL in the CLOZARIL group and 15 mg/dL in the chlorpromazine group. In a pooled data analysis of 2 studies in adult subjects with schizophrenia, CLOZARIL treatment was associated with increases in fasting serum triglyceride. The mean increase in fasting triglyceride was 71 mg/dL (54%) in the CLOZARIL group and 39 mg/dL (35%) in the chlorpromazine group (Table 5). In addition, CLOZARIL treatment was associated with categorical increases in serum total cholesterol and triglyceride, as illustrated in Table 6. The proportion of patients with categorical increases in total cholesterol or fasting triglyceride increased with the duration of exposure. The median duration of CLOZARIL and chlorpromazine exposure was 45 days and 38 days, respectively. The CLOZARIL dose range was 100 mg to 900 mg daily; the maximum chlorpromazine dose was 1800 mg daily.

**Table 5. Mean Changes in Total Cholesterol and Triglyceride Concentration in Studies in Adult Subjects with Schizophrenia**

Treatment Arm	Baseline total cholesterol concentration (mg/dL)	Change from baseline mg/dL (%)
CLOZARIL (N=334)	184	+13 (7)
Chlorpromazine (N=185)	182	+15 (8)
	Baseline triglyceride concentration (mg/dL)	Change from baseline mg/dL (%)
CLOZARIL (N=6)	130	+71 (54)
Chlorpromazine (N=7)	110	+39 (35)

**Table 6. Categorical Changes in Lipid Concentrations in Studies in Adult Subjects with Schizophrenia**

Laboratory Parameter	Category Change (at least once) from baseline	Treatment Arm	N	n (%)
Total Cholesterol (random or fasting)	Increase by $\geq 40$ mg/dL	CLOZARIL	334	111 (33)
		Chlorpromazine	185	46 (25)
	Normal (<200 mg/dL) to High ( $\geq 240$ mg/dL)	CLOZARIL	222	18 (8)
		Chlorpromazine	132	3 (2)
	Borderline (200 – 239 mg/dL) to High ( $\geq 240$ mg/dL)	CLOZARIL	79	30 (38)
		Chlorpromazine	34	14 (41)
Triglycerides (fasting)	Increase by $\geq 50$ mg/dL	CLOZARIL	6	3 (50)
		Chlorpromazine	7	3 (43)
	Normal (<150 mg/dL) to High ( $\geq 200$ mg/dL)	CLOZARIL	4	0 (0)
		Chlorpromazine	6	2 (33)
	Borderline ( $\geq 150$ mg/dL and <200 mg/dL) to High ( $\geq 200$ mg/dL)	CLOZARIL	1	1 (100)
		Chlorpromazine	1	0 (0)

Weight Gain

Weight gain has occurred with the use of antipsychotics, including CLOZARIL. Monitor weight during treatment with CLOZARIL. Table 7 summarizes the data on weight gain by the duration of exposure pooled from 11 studies with CLOZARIL and active comparators. The median duration of exposure was 609, 728, and 42 days, in the CLOZARIL, olanzapine, and chlorpromazine group, respectively.

**Table 7. Mean Change in Body Weight (kg) by Duration of Exposure from Studies in Adult Subjects with Schizophrenia**

Metabolic parameter	Exposure duration	CLOZARIL (N=669)		Olanzapine (N=442)		Chlorpromazine (N=155)	
		n	Mean	n	Mean	n	Mean
Weight change from baseline	2 weeks (Day 11–17)	6	+0.9	3	+0.7	2	-0.5
	4 weeks (Day 21–35)	23	+0.7	8	+0.8	17	+0.6
	8 weeks (Day 49–63)	12	+1.9	13	+1.8	16	+0.9
	12 weeks (Day 70–98)	17	+2.8	5	+3.1	0	0
	24 weeks (Day 154–182)	42	-0.6	12	+5.7	0	0
	48 weeks (Day 322–350)	3	+3.7	3	+13.7	0	0

Table 8 summarizes pooled data from 11 studies in adult subjects with schizophrenia demonstrating weight gain  $\geq 7\%$  of body weight relative to baseline. The median duration of exposure was 609, 728, and 42 days, in the CLOZARIL, olanzapine, and chlorpromazine group, respectively.

**Table 8. Proportion of Adult Subjects in Schizophrenia Studies with Weight Gain  $\geq 7\%$  Relative to Baseline Body Weight**

Weight change	CLOZARIL	Olanzapine	Chlorpromazine
N	669	442	155
$\geq 7\%$ (inclusive)	236 (35%)	203 (46%)	13 (8%)

### 5.11 Neuroleptic Malignant Syndrome

Antipsychotic drugs including CLOZARIL can cause a potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS). Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Associated findings can include elevated creatine phosphokinase (CPK), myoglobinuria, rhabdomyolysis, and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. It is important to consider the presence of other serious medical conditions (e.g., severe neutropenia, infection, heat stroke, primary CNS pathology, central anticholinergic toxicity, extrapyramidal symptoms, and drug fever).

The management of NMS should include (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, (2) intensive symptomatic treatment and medical monitoring, and (3) treatment of comorbid medical conditions. There is no general agreement about specific pharmacological treatments for NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. NMS can recur. Monitor closely if restarting treatment with antipsychotics.

NMS has occurred with CLOZARIL monotherapy and with concomitant CNS-active medications, including lithium.

### 5.12 Hepatotoxicity

Severe, life threatening, and in some cases fatal hepatotoxicity including hepatic failure, hepatic necrosis, and hepatitis have been reported in post marketing studies in patients treated with clozapine [see *Adverse Reactions (6.2)*]. Monitor for the appearance of signs and symptoms of hepatotoxicity such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinemia, coagulopathy, and hepatic encephalopathy. Perform serum tests for liver injury and consider permanently discontinuing treatment if hepatitis or transaminase elevations combined with other systemic symptoms are due to clozapine.

### 5.13 Fever

During clozapine therapy, patients have experienced transient, clozapine-related fever. The peak incidence is within the first 3 weeks of treatment. While this fever is generally benign and self-limited, it may necessitate discontinuing treatment. The fever can be associated with an increase or decrease in WBC count. Carefully evaluate patients with fever to rule out severe neutropenia or infection. Consider the possibility of NMS [see *Warnings and Precautions (5.11)*].

### 5.14 Pulmonary Embolism

Pulmonary embolism and deep-vein thrombosis have occurred in patients treated with CLOZARIL. Consider the possibility of pulmonary embolism in patients who present with deep-vein thrombosis, acute dyspnea, chest pain, or with other respiratory signs and symptoms. Whether pulmonary embolus and deep-vein thrombosis can be attributed to clozapine or some characteristic(s) of patients is not clear.

### 5.15 Anticholinergic Toxicity

CLOZARIL has potent anticholinergic effects. Treatment with CLOZARIL can result in CNS and peripheral anticholinergic toxicity, especially at higher dosages, or in overdose situations [see *Overdosage (10)*]. Use with caution in patients with a current diagnosis or prior history of constipation, urinary retention, clinically significant prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse reactions. When possible, avoid concomitant use, with other anticholinergic medications because the risk for anticholinergic toxicity or severe gastrointestinal adverse reactions is increased [see *Warnings and Precautions (5.7)*, *Drug Interactions (7.1)*].

### **5.16 Interference with Cognitive and Motor Performance**

CLOZARIL can cause sedation and impairment of cognitive and motor performance. Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that CLOZARIL does not affect them adversely. These reactions may be dose-related. Consider reducing the dose if they occur.

### **5.17 Tardive Dyskinesia**

Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs, including CLOZARIL. The syndrome consists of potentially irreversible, involuntary, dyskinetic movements. The risk of TD and the likelihood that it will become irreversible are believed to increase with greater durations of treatment and higher total cumulative doses. However, the syndrome can develop after relatively brief treatment periods at low doses. Prescribe CLOZARIL in a manner that is most likely to minimize the risk of developing TD. Use the lowest effective dose and the shortest duration necessary to control symptoms. Periodically assess the need for continued treatment. Consider discontinuing treatment if TD occurs. However, some patients may require treatment with CLOZARIL despite the presence of the syndrome.

TD may remit partially or completely if treatment is discontinued. Antipsychotic treatment, itself, may suppress (or partially suppress) the signs and symptoms, and it has the potential to mask the underlying process. The effect of symptom suppression on the long-term course of TD is unknown.

### **5.18 Cerebrovascular Adverse Reactions**

In controlled trials, elderly patients with dementia-related psychosis treated with some atypical antipsychotics had an increased risk (compared to placebo) of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities. The mechanism for this increased risk is not known. An increased risk cannot be excluded for CLOZARIL or other antipsychotics or other patient populations. CLOZARIL should be used with caution in patients with risk factors for cerebrovascular adverse reactions.

### **5.19 Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation of CLOZARIL**

If abrupt discontinuation of CLOZARIL is necessary (because of severe neutropenia or another medical condition, for example) [*see Dosage and Administration (2.5), Warnings and Precautions (5.1)*], monitor carefully for the recurrence of psychotic symptoms and adverse reactions related to cholinergic rebound, such as profuse sweating, headache, nausea, vomiting and diarrhea.

## 6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Severe Neutropenia [see *Warnings and Precautions (5.1)*]
- Orthostatic Hypotension, Bradycardia, and Syncope [see *Warnings and Precautions (5.2)*]
- Falls [see *Warnings and Precautions (5.3)*]
- Seizures [see *Warnings and Precautions (5.4)*]
- Myocarditis, Pericarditis, Cardiomyopathy, and Mitral Valve Incompetence [see *Warnings and Precautions (5.5)*]
- Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see *Warnings and Precautions (5.6)*]
- Gastrointestinal Hypomotility with Severe Complications [See *Warnings and Precautions (5.7)*]
- Eosinophilia [see *Warnings and Precautions (5.8)*]
- QT Interval Prolongation [see *Warnings and Precautions (5.9)*]
- Metabolic Changes (Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain) [see *Warnings and Precautions (5.10)*]
- Neuroleptic Malignant Syndrome [see *Warnings and Precautions (5.11)*]
- Hepatotoxicity [see *Warnings and Precautions (5.12)*]
- Fever [see *Warnings and Precautions (5.13)*]
- Pulmonary Embolism [see *Warnings and Precautions (5.14)*]
- Anticholinergic Toxicity [see *Warnings and Precautions (5.15)*]
- Interference with Cognitive and Motor Performance [see *Warnings and Precautions (5.16)*]
- Tardive Dyskinesia [see *Warnings and Precautions (5.17)*]
- Cerebrovascular Adverse Reactions [see *Warnings and Precautions (5.18)*]
- Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation [see *Warnings and Precautions (5.19)*]

### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most commonly reported adverse reactions ( $\geq 5\%$ ) across CLOZARIL clinical trials were: CNS reactions, including sedation, dizziness/vertigo, headache, and tremor; cardiovascular reactions, including tachycardia, hypotension, and syncope; autonomic nervous system reactions, including hypersalivation, sweating, dry mouth, and visual disturbances; gastrointestinal reactions, including constipation and nausea; and fever. [Table 9](#) summarizes the most commonly reported adverse reactions ( $\geq 5\%$ ) in CLOZARIL-treated patients (compared to chlorpromazine-treated patients) in the pivotal, 6-week, controlled trial in treatment-resistant schizophrenia.

**Table 9. Common Adverse Reactions ( $\geq 5\%$ ) in the 6-Week, Randomized, Chlorpromazine-controlled Trial in Treatment-Resistant Schizophrenia**

<b>Adverse Reaction</b>	<b>CLOZARIL (N=126) (%)</b>	<b>Chlorpromazine (N=142) (%)</b>
<b>Sedation</b>	21	13
<b>Tachycardia</b>	17	11
<b>Constipation</b>	16	12
<b>Dizziness</b>	14	16
<b>Hypotension</b>	13	38
<b>Fever (hyperthermia)</b>	13	4
<b>Hypersalivation</b>	13	1
<b>Hypertension</b>	12	5
<b>Headache</b>	10	10
<b>Nausea/vomiting</b>	10	12
<b>Dry mouth</b>	5	20

Table 10 summarizes the adverse reactions reported in CLOZARIL-treated patients at a frequency of 2% or greater across all CLOZARIL studies (excluding the 2-year InterSePT™ Study). These rates are not adjusted for duration of exposure.

**Table 10. Adverse Reactions ( $\geq 2\%$ ) Reported in CLOZARIL-treated Patients (N=842) Across all CLOZARIL Studies (excluding the 2-year InterSePT™ Study)**

Body System Adverse Reaction*	CLOZARIL N=842 Percentage of Patients
<b>Central Nervous System</b>	
Drowsiness/Sedation	39
Dizziness/Vertigo	19
Headache	7
Tremor	6
Syncope	6
Disturbed Sleep/Nightmares	4
Restlessness	4
Hypokinesia/Akinesia	4
Agitation	4
Seizures (convulsions)	3†
Rigidity	3
Akathisia	3
Confusion	3
Fatigue	2
Insomnia	2
<b>Cardiovascular</b>	
Tachycardia	25†
Hypotension	9
Hypertension	4
<b>Gastrointestinal</b>	
Constipation	14
Nausea	5
Abdominal Discomfort/Heartburn	4
Nausea/Vomiting	3
Vomiting	3
Diarrhea	2
<b>Urogenital</b>	
Urinary Abnormalities	2
<b>Autonomic Nervous System</b>	
Salivation	31
Sweating	6
Dry Mouth	6
Visual Disturbances	5
<b>Skin</b>	
Rash	2
<b>Hemic/Lymphatic</b>	
Leukopenia/Decreased WBC/Neutropenia	3
<b>Miscellaneous</b>	
Fever	5
Weight Gain	4
†Rate based on population of approximately 1700 exposed during premarket clinical evaluation of CLOZARIL.	

Table 11 summarizes the most commonly reported adverse reactions ( $\geq 10\%$  of the CLOZARIL or olanzapine group) in the InterSePT™ Study. This was an adequate and well-controlled, two-year study evaluating the efficacy of CLOZARIL relative to olanzapine in reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. The rates are not adjusted for duration of exposure.

**Table 11. Incidence of Adverse Reactions in Patients Treated with CLOZARIL or Olanzapine in the InterSePT™ Study (≥10% in the CLOZARIL or olanzapine group)**

<b>Adverse Reactions</b>	<b>CLOZARIL N=479 % Reporting</b>	<b>Olanzapine N=477 % Reporting</b>
Salivary hypersecretion	48	6
Somnolence	46	25
Weight increased	31	56
Dizziness (excluding vertigo)	27	12
Constipation	25	10
Insomnia	20	33
Nausea	17	10
Vomiting	17	9
Dyspepsia	14	8

### Dystonia

*Class effect:* Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

## **6.2 Postmarketing Experience**

The following adverse reactions have been identified during post-approval use of clozapine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

### Central Nervous System

Delirium, EEG abnormal, myoclonus, paresthesia, possible cataplexy, status epilepticus, obsessive compulsive symptoms, restless leg syndrome and post-discontinuation cholinergic rebound adverse reactions.

### Cardiovascular System

Atrial or ventricular fibrillation, ventricular tachycardia, palpitations, QT interval prolongation, Torsades de Pointes, mitral valve incompetence associated with clozapine-related cardiomyopathy, myocardial infarction, cardiac arrest, myocarditis, pericarditis, and periorbital edema.

### Endocrine System

Pseudopheochromocytoma

### Gastrointestinal System

Acute pancreatitis, dysphagia, salivary gland swelling, colitis, megacolon, fecal incontinence, and intestinal ischemia, infarction, perforation, ulceration or necrosis.

### Hepatobiliary System

Cholestasis, hepatitis, jaundice, hepatotoxicity, hepatic steatosis, hepatic necrosis, hepatic fibrosis, hepatic cirrhosis, liver injury (hepatic, cholestatic, and mixed), and liver failure.

### Immune System Disorders

Angioedema, leukocytoclastic vasculitis.

### Urogenital System

Acute interstitial nephritis, nocturnal enuresis, priapism, renal failure, and retrograde ejaculation.

### Skin and Subcutaneous Tissue Disorders

Hypersensitivity reactions: photosensitivity, vasculitis, erythema multiforme, skin pigmentation disorder, and Stevens-Johnson Syndrome.

### Musculoskeletal System and Connective Tissue Disorders

Myasthenic syndrome, rhabdomyolysis, and systemic lupus erythematosus.

### Respiratory System

Aspiration, pleural effusion, pneumonia, lower respiratory tract infection, sleep apnea.

### Hemic and Lymphatic System

Mild, moderate, or severe leukopenia, agranulocytosis, granulocytopenia, WBC decreased, deep-vein thrombosis, elevated hemoglobin/hematocrit, erythrocyte sedimentation rate (ESR) increased, sepsis, thrombocytosis, and thrombocytopenia.

### Vision Disorders

Narrow-angle glaucoma.

### Miscellaneous

Creatine phosphokinase elevation, hyperuricemia, hyponatremia, polyserositis, and weight loss.

## **7 DRUG INTERACTIONS**

### **7.1 Potential for Other Drugs to Affect CLOZARIL**

Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6. Use caution when administering CLOZARIL concomitantly with drugs that are inducers or inhibitors of these enzymes.

#### CYP1A2 Inhibitors

Concomitant use of CLOZARIL and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the CLOZARIL dose to one-third of the original dose when CLOZARIL is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The CLOZARIL dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [*see Dosage and Administration (2.7), Clinical Pharmacology (12.3)*].

Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. Monitor patients closely when CLOZARIL is coadministered with these inhibitors. Consider reducing the CLOZARIL dosage if necessary [*see Dosage and Administration (2.7)*].

#### CYP2D6 and CYP3A4 Inhibitors

Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [*see Clinical Pharmacology (12.3)*]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [*see Dosage and Administration (2.7)*].

#### CYP1A2 and CYP3A4 Inducers

Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the plasma concentration of clozapine, resulting in decreased effectiveness of CLOZARIL. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, St. John's wort, and rifampin. It may be necessary to increase the CLOZARIL dose if used concomitantly with inducers of these enzymes. However, concomitant use of CLOZARIL and strong CYP3A4 inducers is not recommended [*see Dosage and Administration (2.7)*].

Consider reducing the CLOZARIL dosage when discontinuing coadministered enzyme inducers; because discontinuation of inducers can result in increased clozapine plasma levels and an increased risk of adverse reactions [*see Dosage and Administration (2.7)*].

### Anticholinergic Drugs

Concomitant treatment with clozapine and other drugs with anticholinergic activity (e.g., benztropine, cyclobenzaprine, diphenhydramine) can increase the risk for anticholinergic toxicity and severe gastrointestinal adverse reactions related to hypomotility. Avoid concomitant use of CLOZARIL with anticholinergic drugs when possible [*see Warnings and Precautions (5.7, 5.15)*].

### Drugs that Cause QT Interval Prolongation

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of clozapine. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) [*see Warnings and Precautions (5.9)*].

## **7.2 Potential for CLOZARIL to Affect Other Drugs**

Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including CLOZARIL, during pregnancy. Healthcare providers are encouraged to advise patients to register by calling the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visiting <http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/>.

#### Risk Summary

Neonates exposed to antipsychotic drugs, including CLOZARIL, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms following delivery (*see Clinical Considerations*). Available data from published epidemiologic studies over decades of use with clozapine during pregnancy have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes (*see Data*). There are risks to the mother associated with untreated schizophrenia and with exposure to antipsychotics, including CLOZARIL, during pregnancy (*see Clinical Considerations*).

In animal reproduction studies, no adverse developmental effects were observed when clozapine was administered orally to pregnant rats or rabbits during the period of organogenesis, or to pregnant rats during pregnancy and lactation, at doses up to approximately 0.4 and 0.9 times the maximum recommended human dose (MRHD) of 900 mg/day, for rats and rabbits respectively, based on mg/m<sup>2</sup> body surface area (*see Data*).

The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

## Clinical Considerations

### *Disease-associated maternal and/or embryo/fetal risk*

There is a risk to the mother from untreated schizophrenia, including increased risk of relapse, hospitalization, and suicide. Schizophrenia is associated with increased adverse perinatal outcomes, including preterm birth. It is not known if this is a direct result of the illness or other comorbid factors.

### *Fetal/Neonatal adverse reactions*

Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder have been reported in neonates who have been exposed to antipsychotic drugs, including CLOZARIL, during the third trimester of pregnancy. These symptoms have varied in severity. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization.

## Data

### *Animal Data*

In embryofetal developmental studies, clozapine had no effects on maternal parameters, litter sizes, or fetal parameters when administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 0.4 and 0.9 times, respectively, the MRHD of 900 mg/day on a mg/m<sup>2</sup> body surface area basis.

In peri/postnatal developmental studies, pregnant female rats were administered clozapine over the last third of pregnancy and until day 21 postpartum. Observations were made on fetuses at birth and during the postnatal period; the offspring were allowed to reach sexual maturity and mated. Clozapine caused a decrease in maternal body weight but had no effects on litter size or body weights of either F1 or F2 generations at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m<sup>2</sup> body surface area basis.

## **8.2 Lactation**

### Risk Summary

Clozapine is present in human milk. There is one case report of sedation and a report of agranulocytosis in an infant exposed to clozapine through human milk (*see Clinical Considerations*). There is no information on the effects of clozapine on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for CLOZARIL and any potential adverse effects on the breastfed child from CLOZARIL or from the underlying maternal condition.

## Clinical Considerations

Infants exposed to CLOZARIL should be monitored for excess sedation and neutropenia.

## **8.4 Pediatric Use**

Safety and effectiveness in pediatric patients have not been established.

## **8.5 Geriatric Use**

There have not been sufficient numbers of geriatric patients in clinical studies utilizing CLOZARIL to determine whether those over 65 years of age differ from younger subjects in their response to CLOZARIL.

Orthostatic hypotension and tachycardia can occur with CLOZARIL treatment [*see Boxed Warning and Warnings and Precautions (5.2)*]. Elderly patients, particularly those with compromised cardiovascular functioning, may be more susceptible to these effects.

Elderly patients may be particularly susceptible to the anticholinergic effects of CLOZARIL, such as urinary retention and constipation [*see Warnings and Precautions (5.15)*].

Carefully select CLOZARIL doses in elderly patients, taking into consideration their greater frequency of decreased hepatic, renal, or cardiac function, as well as other concomitant disease and other drug therapy. Clinical experience suggests that the prevalence of tardive dyskinesia appears to be highest among the elderly; especially elderly women [*see Warnings and Precautions (5.17)*].

## 8.6 Patients with Renal or Hepatic Impairment

Dose reduction may be necessary in patients with significant impairment of renal or hepatic function. Clozapine concentrations may be increased in these patients, because clozapine is almost completely metabolized and then excreted [see *Dosage and Administration (2.8), Clinical Pharmacology (12.3)*].

## 8.7 CYP2D6 Poor Metabolizers

Dose reduction may be necessary in patients who are CYP2D6 poor metabolizers. Clozapine concentrations may be increased in these patients, because clozapine is almost completely metabolized and then excreted [see *Dosage and Administration (2.8), Clinical Pharmacology (12.3)*].

# 10 OVERDOSAGE

## 10.1 Overdosage Experience

The most commonly reported signs and symptoms associated with clozapine overdose are: sedation, delirium, coma, tachycardia, hypotension, respiratory depression or failure; and hypersalivation. There are reports of aspiration pneumonia, cardiac arrhythmias, and seizure. Fatal overdoses have been reported with clozapine, generally at doses above 2500 mg. There have also been reports of patients recovering from overdoses well in excess of 4 g.


## 10.2 Management of Overdosage

There is no available specific antidote to an overdose of CLOZARIL. Establish and maintain an airway; ensure adequate oxygenation and ventilation. Monitor cardiac status and vital signs. Use general symptomatic and supportive measures. Consider the possibility of multiple-drug involvement.

Contact a Certified Poison Control Center for the most up to date information on the management of overdose (1-800-222-1222).

# 11 DESCRIPTION

CLOZARIL® (clozapine), an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo [*b,e*] [1,4] diazepine. The structural formula is:



CLOZARIL is available in pale yellow tablets of 25 mg and 100 mg for oral administration.

Active Ingredient: clozapine

Inactive Ingredients are colloidal silicon dioxide, lactose, magnesium stearate, povidone, starch (corn), and talc.

# 12 CLINICAL PHARMACOLOGY

## 12.1 Mechanism of Action

The mechanism of action of clozapine is unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D<sub>2</sub>) and the serotonin type 2A (5-HT<sub>2A</sub>) receptors. CLOZARIL also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.

## 12.2 Pharmacodynamics

Clozapine demonstrated binding affinity to the following receptors: histamine H<sub>1</sub> (K<sub>i</sub> 1.1 nM), adrenergic α<sub>1A</sub> (K<sub>i</sub> 1.6 nM), serotonin 5-HT<sub>6</sub> (K<sub>i</sub> 4 nM), serotonin 5-HT<sub>2A</sub> (K<sub>i</sub> 5.4 nM), muscarinic M<sub>1</sub> (K<sub>i</sub> 6.2 nM), serotonin 5-HT<sub>7</sub> (K<sub>i</sub> 6.3 nM),

serotonin 5-HT<sub>2C</sub> (K<sub>i</sub> 9.4 nM), dopamine D<sub>4</sub> (K<sub>i</sub> 24 nM), adrenergic α<sub>2A</sub> (K<sub>i</sub> 90 nM), serotonin 5-HT<sub>3</sub> (K<sub>i</sub> 95 nM), serotonin 5-HT<sub>1A</sub> (K<sub>i</sub> 120 nM), dopamine D<sub>2</sub> (K<sub>i</sub> 160 nM), dopamine D<sub>1</sub> (K<sub>i</sub> 270 nM), dopamine D<sub>5</sub> (K<sub>i</sub> 454 nM), and dopamine D<sub>3</sub> (K<sub>i</sub> 555 nM).

Clozapine causes little or no prolactin elevation.

Clinical electroencephalogram (EEG) studies demonstrated that clozapine increases delta and theta activity and slows dominant alpha frequencies. Enhanced synchronization occurs. Sharp wave activity and spike and wave complexes may also develop. Patients have reported an intensification of dream activity during clozapine therapy. REM sleep was found to be increased to 85% of the total sleep time. In these patients, the onset of REM sleep occurred almost immediately after falling asleep.

### 12.3 Pharmacokinetics

#### Absorption

In humans, CLOZARIL tablets (25 mg and 100 mg) are equally bioavailable relative to a CLOZARIL solution. Following oral administration of CLOZARIL 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing. The average minimum concentration at steady state was 122 ng/mL (range: 41 to 343 ng/mL), after 100 mg twice daily dosing. Food does not appear to affect the systemic bioavailability of CLOZARIL. Thus, CLOZARIL may be administered with or without food.

#### Distribution

Clozapine is approximately 97% bound to serum proteins. The interaction between clozapine and other highly protein-bound drugs has not been fully evaluated but may be important [*see Drug Interactions (7)*].

#### Metabolism and Excretion

Clozapine is almost completely metabolized prior to excretion, and only trace amounts of unchanged drug are detected in the urine and feces. Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP2D6, and CYP3A4. Approximately 50% of the administered dose is excreted in the urine and 30% in the feces. The demethylated, hydroxylated, and *N*-oxide derivatives are components in both urine and feces. Pharmacological testing has shown the desmethyl metabolite (norclozapine) to have only limited activity, while the hydroxylated and *N*-oxide derivatives were inactive. The mean elimination half-life of clozapine after a single 75 mg dose was 8 hours (range: 4 to 12 hours), compared to a mean elimination half-life of 12 hours (range: 4 to 66 hours), after achieving steady state with 100 mg twice daily dosing.

A comparison of single-dose and multiple-dose administration of clozapine demonstrated that the elimination half-life increased significantly after multiple dosing relative to that after single-dose administration, suggesting the possibility of concentration-dependent pharmacokinetics. However, at steady state, approximately dose-proportional changes with respect to AUC (area under the curve), peak, and minimum clozapine plasma concentrations were observed after administration of 37.5, 75, and 150 mg twice daily.

#### Drug-Drug Interaction Studies

##### Fluvoxamine

A pharmacokinetic study was conducted in 16 patients with schizophrenia who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, *N*-desmethylclozapine and clozapine *N*-oxide, were elevated about three-fold compared to baseline steady-state concentrations.

##### Paroxetine, Fluoxetine, and Sertraline

In a study of patients with schizophrenia (n=14) who received clozapine under steady-state conditions, coadministration of paroxetine produced only minor changes in the levels of clozapine and its metabolites. However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.

## Specific Population Studies

### Renal or Hepatic Impairment

No specific pharmacokinetic studies were conducted to investigate the effects of renal or hepatic impairment on the pharmacokinetics of clozapine. Higher clozapine plasma concentrations are likely in patients with significant renal or hepatic impairment when given usual doses.

### CYP2D6 Poor Metabolizers

A subset (3%–10%) of the population has reduced activity of CYP2D6 (CYP2D6 poor metabolizers). These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.

### Patients with Pneumonia and other Inflammatory Conditions

Published case reports describe examples where pneumonia or other inflammatory conditions may increase clozapine concentrations. The clinical significance, the impact of treatments to modulate this inflammation, and mechanism of this potential increase in clozapine concentrations have not been fully characterized but may involve reduced cytochrome P450 1A2 activity.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

#### Carcinogenesis

No carcinogenic potential was demonstrated in long-term studies in mice and rats at doses up to 0.3 times and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m<sup>2</sup> body surface area basis.

#### Mutagenesis

Clozapine was not genotoxic when tested in the following gene mutation and chromosomal aberration tests: the bacterial Ames test, the *in vitro* mammalian V79 in Chinese hamster cells, the *in vitro* unscheduled DNA synthesis in rat hepatocytes or the *in vivo* micronucleus assay in mice.

#### Impairment of Fertility

Clozapine had no effect on any parameters of fertility, pregnancy, fetal weight or postnatal development when administered orally to male rats 70 days before mating and to female rats for 14 days before mating at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m<sup>2</sup> body surface area basis.

## **14 CLINICAL STUDIES**

### **14.1 Treatment-Resistant Schizophrenia**

The efficacy of CLOZARIL in treatment-resistant schizophrenia was established in a multicenter, randomized, double-blind, active-controlled (chlorpromazine) study in patients with a DSM-III diagnosis of schizophrenia who had inadequate responses to at least 3 different antipsychotics (from at least 2 different chemical classes) during the preceding 5 years. The antipsychotic trials must have been judged adequate; the antipsychotic dosages must have been equivalent to or greater than 1000 mg per day of chlorpromazine for a period of at least 6 weeks, each without significant reduction of symptoms. There must have been no period of good functioning within the preceding 5 years. Patients must have had a baseline score of at least 45 on the investigator-rated Brief Psychiatric Rating Scale (BPRS). On the 18-item BPRS, 1 indicates the absence of symptoms, and 7 indicates severe symptoms; the maximum potential total BPRS score is 126. At baseline, the mean BPRS score was 61. In addition, patients must have had a score of at least 4 on at least two of the following four individual BPRS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content. Patients must have had a Clinical Global Impressions–Severity Scale score of at least 4 (moderately ill).

In the prospective, lead-in phase of the trial, all patients (N=305) initially received single-blind treatment with haloperidol (the mean dose was 61 mg per day) for 6 weeks. More than 80% of patients completed the 6-week trial. Patients with an inadequate response to haloperidol (n=268) were randomized to double-blind treatment with CLOZARIL (N=126) or chlorpromazine (N=142). The maximum daily CLOZARIL dose was 900 mg; the mean daily dose was >600 mg. The maximum daily chlorpromazine dose was 1800 mg; the mean daily dose was >1200 mg.

The primary endpoint was treatment response, predefined as a decrease in BPRS score of at least 20% and either (1) a CGI-S score of  $\leq 3$  (mildly ill), or (2) a BPRS score of  $\leq 35$ , at the end of 6 weeks of treatment. Approximately 88% of patients from the CLOZARIL and chlorpromazine groups completed the 6-week trial. At the end of 6 weeks, 30% of the CLOZARIL group responded to treatment, and 4% of the chlorpromazine group responded to treatment. The difference was statistically significant ( $p < 0.001$ ). The mean change in total BPRS score was -16 and -5 in the CLOZARIL and chlorpromazine group, respectively; the mean change in the 4 key BPRS item scores was -5 and -2 in the CLOZARIL and chlorpromazine group, respectively; and the mean change in CGI-S score was -1.2 and -0.4, in the CLOZARIL and chlorpromazine group, respectively. These changes in the CLOZARIL group were statistically significantly greater than in the chlorpromazine group ( $p < 0.001$  in each analysis).

## 14.2 Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

The effectiveness of CLOZARIL in reducing the risk of recurrent suicidal behavior was assessed in the International Suicide Prevention Trial (InterSePT™, a trademark of Novartis Pharmaceuticals Corporation). This was a prospective, randomized, open-label, active-controlled, multicenter, international, parallel-group comparison of CLOZARIL versus olanzapine (\*Zyprexa®), a registered trademark of Eli Lilly and Company) in 956 patients with schizophrenia or schizoaffective disorder (DSM-IV) who were judged to be at risk for recurrent suicidal behavior. Only about one-fourth of these patients (27%) were considered resistant to standard antipsychotic drug treatment. To enter the trial, patients must have met 1 of the following criteria:

- They had attempted suicide within the three years prior to their baseline evaluation.
- They had been hospitalized to prevent a suicide attempt within the three years prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation with a depressive component within one week prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation accompanied by command hallucinations to do self-harm within one week prior to their baseline evaluation.

Dosing regimens for each treatment group were determined by individual investigators and were individualized by patient. Dosing was flexible, with a dose range of 200–900 mg/day for CLOZARIL and 5–20 mg/day for olanzapine. For the 956 patients who received CLOZARIL or olanzapine in this study, there was extensive use of concomitant psychotropics: 84% with antipsychotics, 65% with anxiolytics, 53% with antidepressants, and 28% with mood stabilizers. There was significantly greater use of concomitant psychotropic medications among the patients in the olanzapine group.


The primary efficacy measure was time to (1) a significant suicide attempt, including a completed suicide; (2) hospitalization due to imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized; or (3) worsening of suicidality severity as demonstrated by “much worsening” or “very much worsening” from baseline in the Clinical Global Impression of Severity of Suicidality as assessed by the Blinded Psychiatrist (CGI-SS-BP) scale. A determination of whether or not a reported event met criterion 1 or 2 above was made by the Suicide Monitoring Board (SMB), a group of experts blinded to patient data.

A total of 980 patients were randomized to the study and 956 received study medication. Sixty-two percent of the patients were diagnosed with schizophrenia, and the remainder (38%) were diagnosed with schizoaffective disorder. Only about one-fourth of the total patient population (27%) was identified as “treatment-resistant” at baseline. There were more males than females in the study (61% of all patients were male). The mean age of patients entering the study was 37 years of age (range 18–69). Most patients were Caucasian (71%), 15% were Black, 1% were Asian, and 13% were classified as being of “other” races.

Patients treated with CLOZARIL had a statistically significant longer delay in the time to recurrent suicidal behavior in comparison with olanzapine. This result should be interpreted only as evidence of the effectiveness of CLOZARIL in delaying time to recurrent suicidal behavior and not a demonstration of the superior efficacy of CLOZARIL over olanzapine.

The probability of experiencing (1) a significant suicide attempt, including a completed suicide, or (2) hospitalization because of imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for CLOZARIL patients than for olanzapine patients at Week 104: CLOZARIL 24% versus olanzapine 32%; 95% CI of the difference: 2%, 14% (Figure 1).

**Figure 1. Cumulative Probability of a Significant Suicide Attempt or Hospitalization to Prevent Suicide in Patients with Schizophrenia or Schizoaffective Disorder at High Risk of Suicidality**



**16 HOW SUPPLIED/STORAGE AND HANDLING**

**16.1 How Supplied**

***CLOZARIL® (clozapine) Tablets***

***25 mg***

Round, pale-yellow, uncoated tablet. Debossed with “CLOZARIL” once on the periphery of one side. Debossed with a facilitated score and “25” once on the other side.

Bottle of 100 ..... NDC 69809-0126-05

***100 mg***

Round, pale-yellow, uncoated tablet. Debossed with “CLOZARIL” once on the periphery of one side. Debossed with a facilitated score and “100” once on the other side.

Bottle of 100 ..... NDC 69809-0127-05

**16.2 Storage and Handling**

Store CLOZARIL at room temperature between 20°C to 25°C (68°F to 77°F); excursion permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

## 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide). Discuss the following issues with patients and caregivers:

- Severe Neutropenia:

Instruct patients (and caregivers) [see *Warnings and Precautions (5.1)*]:

- About the risk of developing severe neutropenia and infection with CLOZARIL treatment.
  - Instruct patients to immediately report to their health care provider any symptom or sign of during CLOZARIL treatment.
  - About the importance of having frequent ANC testing.
- Orthostatic Hypotension, Bradycardia, and Syncope: Inform patients and caregivers about the risk of orthostatic hypotension and syncope, especially during the period of initial dose titration. Instruct them to strictly follow the clinician's instructions for dosage and administration [see *Dosage and Administration (2.2, 2.6)*]. Advise patients to consult their clinician immediately if they feel faint, lose consciousness or have signs or symptoms suggestive of bradycardia or arrhythmia [Warnings and Precautions (5.2)].
  - Seizures: Inform patients and caregivers about the significant risk of seizure during CLOZARIL treatment. Caution them about driving and any other potentially hazardous activity while taking CLOZARIL [see *Warnings and Precautions (5.4)*].
  - Gastrointestinal Hypomotility with Severe Complications: Educate patients and caregivers on the risks, prevention and treatment of clozapine-induced constipation, including medications to avoid when possible (e.g., drugs with anticholinergic activity). Encourage appropriate hydration, physical activity, and fiber intake and emphasize that prompt attention and treatment to the development of constipation or other gastrointestinal symptoms is critical in preventing severe complications. Advise patients and caregivers to contact their health care provider if they experience symptoms of constipation (e.g., difficulty passing stools, incomplete passage of stool, decreased bowel movement frequency) or other symptoms associated with gastrointestinal hypomotility (e.g., nausea, abdominal distension or pain, vomiting) [see *Warnings and Precautions (5.7), Drug Interactions (7.1)*].
  - QT Interval Prolongation: Advise patients to consult their clinician immediately if they feel faint, lose consciousness or have signs or symptoms suggestive of arrhythmia. Instruct patients to not take CLOZARIL with other drugs that cause QT interval prolongation. Instruct patients to inform their clinicians that they are taking CLOZARIL before any new drug [see *Warnings and Precautions (5.9), Drug Interactions (7.1)*].
  - Metabolic Changes (hyperglycemia and diabetes mellitus, dyslipidemia, weight gain): Educate patients and caregivers about the risk of metabolic changes and the need for specific monitoring. The risks include hyperglycemia and diabetes mellitus, dyslipidemia, weight gain, and cardiovascular reactions. Educate patients and caregivers about the symptoms of hyperglycemia (high blood sugar) and diabetes mellitus (e.g., polydipsia, polyuria, polyphagia, and weakness). Monitor all patients for these symptoms. Patients who are diagnosed with diabetes or have risk factors for diabetes (obesity, family history of diabetes) should have their fasting blood glucose monitored before beginning treatment and periodically during treatment. Patients who develop symptoms of hyperglycemia should have assessments of fasting glucose. Clinical monitoring of weight is recommended [see *Warnings and Precautions (5.10)*].
  - Interference with Cognitive and Motor Performance: Because CLOZARIL may have the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that CLOZARIL therapy does not affect them adversely [see *Warnings and Precautions (5.16)*].
  - Missed Doses and Re-initiating Treatment: Inform patients and caregivers that if the patient misses taking CLOZARIL for 1 day or more, they should not restart their medication at the same dosage but should contact their physician for dosing instructions [see *Dosage and Administration (2.6), Warnings and Precautions (5.1, 5.2)*].

- *Pregnancy*: Advise pregnant women to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with CLOZARIL. Advise patients that CLOZARIL may cause extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder) in a neonate. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to CLOZARIL during pregnancy [*see Use in Specific Populations (8.1)*].
- *Lactation*: Advise breastfeeding women using CLOZARIL to monitor infants for excess sedation and to seek medical care if they notice this sign. Inform breastfeeding women using CLOZARIL that their healthcare provider will monitor infants for neutropenia [*see Use in Specific Populations (8.2)*].
- *Concomitant Medication*: Advise patients to inform their healthcare provider if they are taking, or plan to take, any prescription or over-the-counter drugs; there is a potential for significant drug-drug interactions [*see Dosage and Administration (2.7), Drug Interactions (7.1)*].

Distributed by: HLS Therapeutics (USA), Inc.

Rosemont, PA 19010

(844) 457-8721

© HLS Therapeutics

MLR USA: 20250603

2025HER001

June 2025

\*Zyprexa<sup>®</sup> (olanzapine) is a registered trademark of Eli Lilly and Company.

\*\*Trademark of Thomson Healthcare, Inc.

CLOZARIL<sup>®</sup> is a registered trademark of Novartis Pharmaceuticals Corporation.